S&P lifts Schering-Plough view to stable

Standard & Poor's said it revised its outlook on Schering-Plough Corp. to stable from negative.

Ratings on the company, including the A- long-term corporate credit rating and A-2 short-term rating, were affirmed.

The outlook revision is based on Schering-Plough's improving operational performance, led by its cholesterol lowering franchise, Vytorin/Zetia and continued maintenance of its conservative financial profile, the agency said.

S&P added that the ratings on the company continue to reflect its diverse product portfolio, featuring major products Vytorin/Zetia, Remicade, PEG-Intron and Clarinex, as well as its conservative financial profile.

These factors are partially offset by the challenges Schering-Plough faces in reinvigorating its near-term product pipeline, S&P noted.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.